Adjunctive Dapagliflozin Improves Glycemic Control in T1D
Dapagliflozin, when used as adjunct treatment to insulin, improves glycemic control in patients with type 1 diabetes.
After 52 weeks, dapagliflozin was well tolerated and led to a clinically relevant improvement in glycemic control and weight loss without additional risk for hypoglycemia.
"This is the first report of decreased insulin requirements in a patient with [T1D] correlating with micafungin administration," noted the authors.
There is a dose-dependent association between smoking and coronary heart disease in patients with type 1 diabetes.